218 related articles for article (PubMed ID: 30397852)
1. PD-L1 Expression on Lung Cancer Stem Cells in Metastatic Lymph Nodes Aspirates.
Raniszewska A; Polubiec-Kownacka M; Rutkowska E; Domagala-Kulawik J
Stem Cell Rev Rep; 2019 Apr; 15(2):324-330. PubMed ID: 30397852
[TBL] [Abstract][Full Text] [Related]
2. PD-L1
Raniszewska A; Vroman H; Dumoulin D; Cornelissen R; Aerts JGJV; Domagała-Kulawik J
Cancer Immunol Immunother; 2021 Feb; 70(2):453-461. PubMed ID: 32808188
[TBL] [Abstract][Full Text] [Related]
3. EBUS-TBNA as a Promising Method for the Evaluation of Tumor PD-L1 Expression in Lung Cancer.
Sakakibara R; Inamura K; Tambo Y; Ninomiya H; Kitazono S; Yanagitani N; Horiike A; Ohyanagi F; Matsuura Y; Nakao M; Mun M; Okumura S; Inase N; Nishio M; Motoi N; Ishikawa Y
Clin Lung Cancer; 2017 Sep; 18(5):527-534.e1. PubMed ID: 28111119
[TBL] [Abstract][Full Text] [Related]
4. Immunosuppressive properties of human PD-1 + , PDL-1 + and CD80 + dendritic cells from lymph nodes aspirates of lung cancer patients.
Kwiecień I; Rutkowska E; Raniszewska A; Sokołowski R; Bednarek J; Jahnz-Różyk K; Rzepecki P; Domagała-Kulawik J
Cancer Immunol Immunother; 2022 Oct; 71(10):2469-2483. PubMed ID: 35254478
[TBL] [Abstract][Full Text] [Related]
5. Heterogeneity analysis of PD-L1 expression and copy number status in EBUS-TBNA biopsy specimens of non-small cell lung cancer: Comparative assessment of primary and metastatic sites.
Yoshimura K; Inoue Y; Karayama M; Tsuchiya K; Mori K; Suzuki Y; Iwashita Y; Kahyo T; Kawase A; Tanahashi M; Ogawa H; Yokomura K; Inui N; Funai K; Shinmura K; Niwa H; Suda T; Sugimura H
Lung Cancer; 2019 Aug; 134():202-209. PubMed ID: 31319982
[TBL] [Abstract][Full Text] [Related]
6. Immunomodulatory Molecules On Lung Cancer Stem Cells From Lymph Nodes Aspirates.
Raniszewska A; Kwiecień I; Sokołowski R; Rutkowska E; Domagała-Kulawik J
Cancers (Basel); 2020 Mar; 12(4):. PubMed ID: 32244422
[TBL] [Abstract][Full Text] [Related]
7. The immune checkpoint, HVEM may contribute to immune escape in non-small cell lung cancer lacking PD-L1 expression.
Ren S; Tian Q; Amar N; Yu H; Rivard CJ; Caldwell C; Ng TL; Tu M; Liu Y; Gao D; Ellison K; Suda K; Rozeboom L; Rivalland G; Mitchell P; Zhou C; Hirsch FR
Lung Cancer; 2018 Nov; 125():115-120. PubMed ID: 30429008
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Programmed Death Ligand-1 Immunohistochemical Staining Between Endobronchial Ultrasound Transbronchial Needle Aspiration and Resected Lung Cancer Specimens.
Sakata KK; Midthun DE; Mullon JJ; Kern RM; Nelson DR; Edell ES; Schiavo DN; Jett JR; Aubry MC
Chest; 2018 Oct; 154(4):827-837. PubMed ID: 30059678
[TBL] [Abstract][Full Text] [Related]
9. PD-L1 testing on the EBUS-FNA cytology specimens of non-small cell lung cancer.
Wang G; Ionescu DN; Lee CH; Hiruki T; Myers R; Shaipanich T; Lam S; Melosky B; Zhou C
Lung Cancer; 2019 Oct; 136():1-5. PubMed ID: 31421256
[TBL] [Abstract][Full Text] [Related]
10. Tumor-draining lymph nodes demonstrate a suppressive immunophenotype in patients with non-small cell lung cancer assessed by endobronchial ultrasound-guided transbronchial needle aspiration: A pilot study.
Murthy V; Katzman DP; Tsay JJ; Bessich JL; Michaud GC; Rafeq S; Minehart J; Mangalick K; de Lafaille MAC; Goparaju C; Pass H; Sterman DH
Lung Cancer; 2019 Nov; 137():94-99. PubMed ID: 31563736
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of cancer stem cells, epithelial-mesenchymal transition and circulating tumor cells in lung cancer.
Pirozzi G; Tirino V; Camerlingo R; La Rocca A; Martucci N; Scognamiglio G; Franco R; Cantile M; Normanno N; Rocco G
Oncol Rep; 2013 May; 29(5):1763-8. PubMed ID: 23426441
[TBL] [Abstract][Full Text] [Related]
12. Circulating tumor cells in pulmonary vein and peripheral arterial provide a metric for PD-L1 diagnosis and prognosis of patients with non-small cell lung cancer.
Dong J; Zhu D; Tang X; Lu D; Qiu X; Li B; Lin D; Li L; Liu J; Zhou Q
PLoS One; 2019; 14(7):e0220306. PubMed ID: 31348821
[TBL] [Abstract][Full Text] [Related]
13. Heterogeneous Expression of Programmed Death Receptor-ligand 1 on Circulating Tumor Cells in Patients With Lung Cancer.
Koh Y; Yagi S; Akamatsu H; Kanai K; Hayata A; Tokudome N; Akamatsu K; Higuchi M; Kanbara H; Nakanishi M; Ueda H; Yamamoto N
Clin Lung Cancer; 2019 Jul; 20(4):270-277.e1. PubMed ID: 31005568
[TBL] [Abstract][Full Text] [Related]
14. Clinical performance of endobronchial ultrasound-guided transbronchial needle aspiration for assessing programmed death ligand-1 expression in nonsmall cell lung cancer.
Biswas A; Leon ME; Drew P; Fernandez-Bussy S; Furtado LV; Jantz MA; Mehta HJ
Diagn Cytopathol; 2018 May; 46(5):378-383. PubMed ID: 29476608
[TBL] [Abstract][Full Text] [Related]
15. Programmed Cell Death Ligand (PD-L1) Expression in Stage II and III Lung Adenocarcinomas and Nodal Metastases.
Uruga H; Bozkurtlar E; Huynh TG; Muzikansky A; Goto Y; Gomez-Caraballo M; Hata AN; Gainor JF; Mark EJ; Engelman JA; Lanuti MD; Mino-Kenudson M
J Thorac Oncol; 2017 Mar; 12(3):458-466. PubMed ID: 27815126
[TBL] [Abstract][Full Text] [Related]
16. Comparison of
Erber R; Stöhr R; Herlein S; Giedl C; Rieker RJ; Fuchs F; Ficker JH; Hartmann A; Veltrup E; Wirtz RM; Brueckl WM
Anticancer Res; 2017 Dec; 37(12):6771-6778. PubMed ID: 29187455
[TBL] [Abstract][Full Text] [Related]
17. Insluin and epithelial growth factor (EGF) promote programmed death ligand 1(PD-L1) production and transport in colon cancer stem cells.
Chen M; Sharma A; Lin Y; Wu Y; He Q; Gu Y; Xu ZP; Monteiro M; Gu W
BMC Cancer; 2019 Feb; 19(1):153. PubMed ID: 30770752
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathological correlation of PD-L1 expression in primary and metastatic breast cancer and infiltrating immune cells.
Tawfik O; Kimler BF; Karnik T; Shehata P
Hum Pathol; 2018 Oct; 80():170-178. PubMed ID: 29936058
[TBL] [Abstract][Full Text] [Related]
19. The critical role of EBUS-TBNA cytology in the staging of mediastinal lymph nodes in lung cancer patients: A correlation study with positron emission tomography findings.
Lilo MT; Allison DB; Younes BK; Cui M; Askin FB; Gabrielson E; Li QK
Cancer Cytopathol; 2017 Sep; 125(9):717-725. PubMed ID: 28609021
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of PD-L1 expression on vortex-isolated circulating tumor cells in metastatic lung cancer.
Dhar M; Wong J; Che J; Matsumoto M; Grogan T; Elashoff D; Garon EB; Goldman JW; Sollier Christen E; Di Carlo D; Kulkarni RP
Sci Rep; 2018 Feb; 8(1):2592. PubMed ID: 29416054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
